-
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-20 Lyduine E. Collij, Ariane Bollack, Renaud La Joie, Mahnaz Shekari, Santiago Bullich, Núria Roé-Vellvé, Norman Koglin, Aleksandar Jovalekic, David Valléz Garciá, Alexander Drzezga, Valentina Garibotto, Andrew W. Stephens, Mark Battle, Christopher Buckley, Frederik Barkhof, Gill Farrar, Juan Domingo Gispert
Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology
-
Unsuccessful transmissions of atypical genetic Creutzfeldt–Jakob disease (PRNP p.T183A-129M) in transgenic mice Acta Neuropathol. (IF 9.3) Pub Date : 2024-11-20 Simone Baiardi, Claudia Marina Vargiu, Shirou Mohri, Otto Windl, Jochen Herms, Sabina Capellari, Tetsuyuki Kitamoto, Piero Parchi
-
The emerging field of non-invasive brain stimulation in Alzheimer’s disease Brain (IF 10.6) Pub Date : 2024-11-20 Giacomo Koch, Daniele Altomare, Alberto Benussi, Lucie Bréchet, Elias P Casula, Alessandra Dodich, Michela Pievani, Emiliano Santarnecchi, Giovanni B Frisoni
Treating cognitive impairment is a holy grail of modern clinical neuroscience. In the past few years, non-invasive brain stimulation is increasingly emerging as a therapeutic approach to ameliorate performance in patients with cognitive impairment and as an augmentation approach in persons whose cognitive performance is within normal limits. In patients with Alzheimer’s disease, better understanding
-
Synaptic and cognitive impairment associated with L444P heterozygous glucocerebrosidase mutation Brain (IF 10.6) Pub Date : 2024-11-20 Wudu Lado, Ahrom Ham, Hongyu Li, Hong Zhang, Audrey Yuen Chang, Sergio Pablo Sardi, Roy N Alcalay, Ottavio Arancio, Serge Przedborsky, Guomei Tang
Cognitive impairment is a common but poorly understood non-motor aspect of Parkinson’s disease, negatively affecting patient’s functional capacity and quality of life. The mechanisms underlying cognitive impairment in Parkinson’s disease are still elusive, limiting treatment and prevention strategies. This study investigates the molecular and cellular basis of cognitive impairment associated with heterozygous
-
Homocysteine, neurodegenerative biomarkers, and APOE ε4 in neurodegenerative diseases Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 William Z. Lin, Di Yu, Lisa Y. Xiong, Julia Zebarth, Ruoding Wang, Corinne E. Fischer, Tarek K. Rajji, David F. Tang-Wai, Carmela Tartaglia, Gustavo Saposnik, Richard H. Swartz, David A. Grimes, Anthony E. Lang, Robert A. Hegele, Sali Farhan, Joel Ramirez, Sean Symons, Maged Goubran, Malcolm A. Binns, Wendy Lou, Roger A. Dixon, Joseph B. Orange, Angela C. Roberts, Angela K. Troyer, Henrik Zetterberg
Elevated plasma homocysteine (Hcy) is associated with an increased risk of developing neurodegenerative diseases; however, its relationship with the apolipoprotein E (APOE) ε4 allele has not been well characterized.
-
Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Susan M. Landau, Theresa M. Harrison, Suzanne L. Baker, Martin S. Boswell, JiaQie Lee, Jacinda Taggett, Tyler J. Ward, Trevor Chadwick, Alice Murphy, Charles DeCarli, Christopher G. Schwarz, Prashanthi Vemuri, Clifford R. Jack, Robert A. Koeppe, William J. Jagust
A key goal of the Alzheimer's Disease NeuroImaging Initiative (ADNI) positron emission tomography (PET) Core is to harmonize quantification of β-amyloid (Aβ) and tau PET image data across multiple scanners and tracers.
-
Stearoyl-CoA desaturase-1: a potential therapeutic target for neurological disorders Mol. Neurodegener. (IF 14.9) Pub Date : 2024-11-19 Melanie Loix, Sam Vanherle, Marta Turri, Stephan Kemp, Karl J. L. Fernandes, Jerome J. A. Hendriks, Jeroen F. J. Bogie
Disturbances in the fatty acid lipidome are increasingly recognized as key drivers in the progression of various brain disorders. In this review article, we delve into the impact of Δ9 fatty acid desaturases, with a particular focus on stearoyl-CoA desaturase-1 (SCD1), within the setting of neuroinflammation, neurodegeneration, and brain repair. Over the past years, it was established that inhibition
-
Neighborhood physical activity facilities predict risk of incident mixed and vascular dementia: The Cardiovascular Health Cognition Study Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Kyle D. Moored, Michael R. Desjardins, Breanna M. Crane, Patrick T. Donahue, Emily A. Richards, Jana A. Hirsch, Gina S. Lovasi, Andrea L. Rosso, Parveen K. Garg, Timothy M. Shields, Frank C. Curriero, Michelle C. Odden, Oscar L. Lopez, Mary L. Biggs, Anne B. Newman, Michelle C. Carlson
INTRODUCTIONNeighborhood environments may promote neurocognitive health in part by providing amenities that encourage physical activity. We examined associations between quantity of walkable facilities, including specifically physical activity facilities (e.g., gyms, recreation centers), with risk of incident dementia.METHODSParticipants included 2923 adults ≥ 65 years old from the Cardiovascular Health
-
Plasma p‐tau181 and GFAP reflect 7T MR‐derived changes in Alzheimer's disease: A longitudinal study of structural and functional MRI and MRS Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Laura Göschel, Andrea Dell'Orco, Ariane Fillmer, Semiha Aydin, Bernd Ittermann, Layla Riemann, Sylvain Lehmann, Stefan Cano, Jeanette Melin, Leslie Pendrill, Patty L. Hoede, Charlotte E. Teunissen, Claudia Schwarz, Ulrike Grittner, Péter Körtvélyessy, Agnes Flöel
BACKGROUNDAssociations between longitudinal changes of plasma biomarkers and cerebral magnetic resonance (MR)‐derived measurements in Alzheimer's disease (AD) remain unclear.METHODSIn a study population (n = 127) of healthy older adults and patients within the AD continuum, we examined associations between longitudinal plasma amyloid beta 42/40 ratio, tau phosphorylated at threonine 181 (p‐tau181)
-
Marmosets as model systems for the study of Alzheimer's disease and related dementias: Substantiation of physiological tau 3R and 4R isoform expression and phosphorylation Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Hasi Huhe, Sarah M. Shapley, Duc M. Duong, Fang Wu, Seung‐Kwon Ha, Sang‐Ho Choi, Julia Kofler, Yongshan Mou, Thais Rafael Guimaraes, Amantha Thathiah, Caroline M. Watson, Lauren K. H. Schaeffer, Gregory W. Carter, Nicholas T. Seyfried, Afonso C. Silva, Stacey J. Sukoff Rizzo
INTRODUCTIONMarmosets spontaneously develop pathological hallmarks of Alzheimer's disease (AD) including amyloid beta plaques. However, tau expression in the marmoset brain has been understudied.METHODSIsoforms of tau were examined by western blot, mass spectrometry, immunofluorescence, and immunohistochemical staining.RESULTS3R and 4R tau isoforms are expressed in marmoset brains at both the transcript
-
Association of precuneus Aβ burden with default mode network function Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Liang Cui, Zhen Zhang, You‐Yi Tu, Min Wang, Yi‐Hui Guan, Yue‐Hua Li, Fang Xie, Qi‐Hao Guo
INTRODUCTIONIt remains unclear whether the local amyloid‐beta (Aβ) burden in key regions within the default mode network (DMN) affects network and cognitive functions.METHODSParticipants included 1002 individuals from the Chinese Preclinical Alzheimer's Disease Study cohort who underwent 18F‐florbetapir positron emission tomography resting‐state functional magnetic resonance imaging scanning and neuropsychological
-
Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Julia Perry, Katrin Radenbach, Katharina Geschke, Ayda Rostamzadeh
New possibilities of biomarker‐based predictive technologies for Alzheimer's disease (AD) have become more reliable as well as more accessible. Standardized clinical recommendations and guidance for counseling and disclosure in this context are not yet well developed. Our scoping review identified publications from database searches in PubMed, PsycINFO, LIVIVO, and Web of Science. Inclusion criteria
-
The pathogenicity of PSEN2 variants is tied to Aβ production and homology to PSEN1 Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Lei Liu, Stephanie A. Schultz, Adriana Saba, Hyun‐Sik Yang, Amy Li, Dennis J. Selkoe, Jasmeer P. Chhatwal
INTRODUCTIONThough recognized as a potential cause of autosomal dominant Alzheimer's disease, the pathogenicity of many PSEN2 variants remains uncertain. We compared amyloid beta (Aβ) production across all missense PSEN2 variants in the AlzForum database and, when possible, to corresponding PSEN1 variants.METHODSWe expressed 74 PSEN2 variants, 21 of which had known, homologous PSEN1 pathogenic variants
-
Caregiver perspectives enable accurate diagnosis of neurodegenerative disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Alexander G. Murley, Lucy Bowns, Marta Camacho, Caroline H. Williams‐Gray, Kamen A. Tsvetanov, Timothy Rittman, Roger A. Barker, John T. O'Brien, James B. Rowe
BACKGROUNDThe history from a relative or caregiver is an important tool for differentiating neurodegenerative disease. We characterized patterns of caregiver questionnaire responses, at diagnosis and follow‐up, on the Cambridge Behavioural Inventory (CBI).METHODSData‐driven multivariate analysis (n = 4952 questionnaires) was undertaken for participants (n = 2481) with Alzheimer's disease (typical/amnestic
-
Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Ramiro Eduardo Rea Reyes, Karly A. Cody, Rachael E. Wilson, Henrik Zetterberg, Nathaniel A. Chin, Erin M. Jonaitis, Melissa Bahr, Olivia Mandel, Madilynn Wintlend, Barbara B. Bendlin, Ozioma C. Okonkwo, Lindsay R. Clark, Matt Zammit, Sanjay Asthana, Bradley T. Christian, Tobey J. Betthauser, Laura Eisenmenger, Rebecca E. Langhough, Sterling C. Johnson
INTRODUCTIONPatterns of signal from tau positron emission tomography (tau‐PET) confined to the medial temporal lobe (MTL) or extended into the neocortex may be relevant for Alzheimer's disease (AD) research if they are linked to differential biomarker levels and cognitive decline.METHODSVisual assessment of Tau‐PET [F‐18]florquinitau (FQT) exams from 728 initially non‐demented older adults yielded
-
Genetic variants associated with age‐related episodic memory decline implicate distinct memory pathologies Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Amanat Ali, Sofiya Milman, Erica F. Weiss, Tina Gao, Valerio Napolioni, Nir Barzilai, Zhengdong D. Zhang, Jhih‐Rong Lin
BACKGROUNDApproximately 40% of people aged ≥ 65 experience memory loss, particularly in episodic memory. Identifying the genetic basis of episodic memory decline is crucial for uncovering its underlying causes.METHODSWe investigated common and rare genetic variants associated with episodic memory decline in 742 (632 for rare variants) Ashkenazi Jewish individuals (mean age 75) from the LonGenity study
-
Conversion to Alzheimer's disease dementia from normal cognition directly or with the intermediate mild cognitive impairment stage Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Xinlin Lu, Yahui Zhang, Yichen Tang, Charles Bernick, Guogen Shan
INTRODUCTIONProgression to Alzheimer's disease (AD) dementia from normal cognition (NC) can follow different trajectories, with most progressing through a recognizable mild cognitive impairment stage (NC–MCI–AD), while some individuals transition quickly from NC to AD dementia (NC–AD).METHODSWe compared demographic characteristics, health factors, and cognitive and functional assessments across three
-
Long‐term effects of collaborative dementia care on quality of life and caregiver well‐being Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-19 Katherine L. Possin, Sarah Dulaney, Alissa B. Sideman, Andrew J. Wood, I. Elaine Allen, Stephen J. Bonasera, Jennifer J. Merrilees, Kirby Lee, Winston Chiong, Tamara L. Braley, Sarah Hooper, Mia Kanzawa, Rosalie Gearhart, Helen Medsger, Krista L. Harrison, Lauren J. Hunt, Rachel E. Kiekhofer, Christopher Chow, Bruce L. Miller, Elan L. Guterman
INTRODUCTIONCollaborative dementia care models with care navigation, including the Care Ecosystem, improve outcomes for persons living with dementia (PLWDs) and their caregivers. The effects of continuous care over long periods have not been studied.METHODSIn this randomized clinical trial with 456 PLWD–caregiver dyads with high caregiver burden, we evaluated the cumulative 5‐year treatment effect
-
Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa‐Foscarbidopa Hydrate: Histopathology Mov. Disord. (IF 7.4) Pub Date : 2024-11-19 Nagisa Yoshihara, Noriko Nishikawa, Rei Watanabe, Nobutaka Hattori
-
Stimulation‐Evoked Resonant Neural Activity in the Subthalamic Nucleus Is Modulated by Sleep Mov. Disord. (IF 7.4) Pub Date : 2024-11-19 Christoph Wiest, Thomas G. Simpson, Alek Pogosyan, Harutomo Hasegawa, Shenghong He, Fernando Rodriguez Plazas, Laura Wehmeyer, Sahar Yassine, Xuanjun Guo, Rahul Shah, Anca Merla, Andrea Perera, Ahmed Raslan, Andrew O'Keeffe, Michael G. Hart, Francesca Morgante, Erlick A. Pereira, Keyoumars Ashkan, Huiling Tan
BackgroundDeep brain stimulation is a treatment for advanced Parkinson's disease and currently tuned to target motor symptoms during daytime. Parkinson's disease is associated with multiple nocturnal symptoms such as akinesia, insomnia, and sleep fragmentation, which may require adjustments of stimulation during sleep for best treatment outcome.ObjectivesThere is a need for a robust biomarker to guide
-
Omaveloxolone for the Treatment of Friedreich Ataxia: Efficacy, Safety, and Future Perspectives Mov. Disord. (IF 7.4) Pub Date : 2024-11-19 Saba Naghipour, Louise A. Corben, Amy J. Hulme, Mirella Dottori, Martin B. Delatycki, Jarmon G. Lees, Shiang Y. Lim
-
Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early Alzheimer Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-11-18 Stephen Salloway, Jakub Wojtowicz, Nicola Voyle, Christopher A. Lane, Gregory Klein, Marco Lyons, Simona Rossomanno, Francesca Mazzo, Szofia Bullain, Frederik Barkhof, Tobias Bittner, Andres Schneider, Michael Grundman, Roxana Aldea, Mercè Boada, Janice Smith, Rachelle Doody
ImportanceData from 2 phase 3 studies of gantenerumab, GRADUATE I/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae.ObjectivesTo describe the characteristics of ARIA and risk factors and clinical consequences of ARIA-edema (ARIA-E).Design, Setting, and ParticipantsSecondary data collection from
-
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis JAMA Neurol. (IF 20.4) Pub Date : 2024-11-18 Sara Terrim, João Vitor Mahler, Flávio Vieira Marques Filho, Leandro Tavares Lucato, Henrique Mayrink Giardini, Tarso Adoni, Guilherme Diogo Silva
ImportanceImmunoglobulin G4 (IgG4)–related disease is an increasingly recognized fibroinflammatory condition that can involve multiple organs, including the pachymeninges. The understanding of IgG4-related pachymeningitis (IgG4-RP) remains limited because of its rarity and the predominance of knowledge derived from case reports and case series.ObjectiveTo systematically review and synthesize the clinical
-
Spontaneous cerebrovascular reactivity at rest in older adults with and without mild cognitive impairment and memory deficits Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-18 Allison C. Engstrom, John Paul M. Alitin, Arunima Kapoor, Shubir Dutt, Trevor Lohman, Isabel J. Sible, Anisa J. Marshall, Fatemah Shenasa, Aimée Gaubert, Farrah Ferrer, Amy Nguyen, David Robert Bradford, Kathleen Rodgers, Lorena Sordo, Elizabeth Head, Xingfeng Shao, Danny J. J. Wang, Daniel A. Nation
INTRODUCTIONOlder adults with mild cognitive impairment (MCI) exhibit deficits in cerebrovascular reactivity (CVR), suggesting CVR is a biomarker for vascular contributions to MCI. This study examined if spontaneous CVR is associated with MCI and memory impairment.METHODSOne hundred sixty‐one older adults free of dementia or major neurological/psychiatric disorders were recruited. Participants underwent
-
Use of common cardiovascular disease drugs and risk of dementia: A case–control study in Swedish national register data Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-18 Mozhu Ding, Alexandra M. Wennberg, Gunnar Engström, Karin Modig
INTRODUCTIONCardiovascular drug use may help prevent dementia; however, current evidence is mixed. Using a case–control design, we investigated the association between duration and combination of multiple cardiovascular drug classes and incident dementia.METHODSFrom the Swedish national registers, we included 88,065 incident dementia cases aged ≥ 70 at diagnosis between 2011 and 2016 and 880,650 age‐
-
Three-dimensional tissue engineered skeletal muscle modelling facioscapulohumeral muscular dystrophy Brain (IF 10.6) Pub Date : 2024-11-18 Marnix Franken, Erik van der Wal, Dongxu Zheng, Bianca den Hamer, Patrick J van der Vliet, Richard J L F Lemmers, Anita van den Heuvel, Alexandra L Dorn, Cas G A Duivenvoorden, Stijn L M in’t Groen, Christian Freund, Bert Eussen, Rabi Tawil, Baziel G M van Engelen, Pim W W M P Pijnappel, Silvère M van der Maarel, Jessica C de Greef
Facioscapulohumeral muscular dystrophy (FSHD) is caused by sporadic misexpression of the transcription factor double homeobox 4 (DUX4) in skeletal muscles. So far, monolayer cultures and animal models have been used to study the FSHD disease mechanism and for FSHD therapy development, but these models do not fully recapitulate the disease and there is a lack of knowledge on how DUX4 misexpression leads
-
Modifiable Risk Factors for Subarachnoid Hemorrhage: Narrative Review With an Emphasis on Common Controversies and Epidemiologic Pitfalls. Neurology (IF 7.7) Pub Date : 2024-11-18 Ilari Matias Rautalin,Aleksanteri Asikainen,Miikka Korja
Given the relatively low incidence, high prehospital death rate, substantial geographical differences, and complex disease origin (combination of genetic and environmental risk factors), epidemiologic research on subarachnoid hemorrhage (SAH) and its risk factors is challenging. In practice, we are more or less forced to exploit compromised study designs and nonrepresentative data in such circumstances
-
Neuropsychological Outcomes After Stereo-EEG Radiofrequency Thermocoagulation. Neurology (IF 7.7) Pub Date : 2024-11-18 Emily Cockle,Charles B Malpas,Honor Coleman,Alissandra McIlroy,Joshua Laing,Patrick Kwan,Martin Hunn,Matthew Gutman,Cecilia Harb,Cathermine Meade,Wendyl J D'Souza,Amy J Halliday,Kristian Bulluss,Simon J Vogrin,Rubina Alpitsis,Terence J O'Brien,Genevieve Rayner,Andrew Neal
BACKGROUND AND OBJECTIVES Stereo-EEG-guided radiofrequency thermocoagulation (RFTHC) has been proposed as relatively safe from a cognitive perspective; however, there is a lack of evidence based on neuropsychological assessments supporting this. This study is the first prospective evaluation of neuropsychological outcomes associated with stereo-EEG-guided RFTHC in patients with focal drug-resistant
-
Association of Conscious Sedation With Dexmedetomidine and Outcome in Stroke Patients Undergoing Thrombectomy in the DEVT and RESCUE-BT Trials. Neurology (IF 7.7) Pub Date : 2024-11-18 Chen Gong,Jiacheng Huang,Zhongming Qiu,Meng Guo,Liyuan Chen,Hongfei Sang,Weilin Kong,Liping Huang,Pan Hu,Yangmei Chen,Fengli Li,Thanh N Nguyen,Chang Liu
BACKGROUND AND OBJECTIVES Although dexmedetomidine (DEX) is widely administered during endovascular treatment (EVT) to enhance procedural adherence of patients with acute ischemic stroke (AIS) with large vessel occlusion, there is limited research on the association of DEX and outcomes among these patients. Hence, this study aimed to explore the safety and outcomes of DEX during conscious sedation
-
Is Dexmedetomidine Safe for Procedural Sedation During Mechanical Thrombectomy for Acute Stroke Secondary to Large Vessel Occlusion? Neurology (IF 7.7) Pub Date : 2024-11-18 Zurab Nadareishvili,Dileep R Yavagal
-
18F-Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies. Mov. Disord. (IF 7.4) Pub Date : 2024-11-18 Gan Tang,Jia-Ying Lu,Xin-Yi Li,Rui-Xin Yao,Yu-Jie Yang,Fang-Yang Jiao,Ming-Jia Chen,Xiao-Niu Liang,Zi-Zhao Ju,Jing-Jie Ge,Yi-Xin Zhao,Bo Shen,Ping Wu,Yi-Min Sun,Jian-Jun Wu,Tzu-Chen Yen,Chuantao Zuo,Jian Wang,Qian-Hua Zhao,Hui-Wei Zhang,Feng-Tao Liu,
BACKGROUND Dementia with Lewy bodies (DLB) commonly exhibits a complex neuropathology, sharing characteristics with Alzheimer's disease (AD), including tau aggregates. However, studies using the 18F-AV-1451 tau tracer have shown inconsistent findings regarding both the extent and topographical distribution of tau pathology in DLB. OBJECTIVES Our aim was to elucidate the topographical patterns of tau
-
Are oligodendrocytes the missing link in Alzheimer’s disease and related dementia research? Mol. Neurodegener. (IF 14.9) Pub Date : 2024-11-17 Sharyn L. Rossi, Diane E. Bovenkamp
Oligodendrocytes (OLs) and their lineage progenitor (OPCs) and precursor cells are widely studied and recognized as promising therapeutic targets for multiple neurodegenerative diseases and disorders including multiple sclerosis, spinal cord injuries, traumatic brain injuries, stroke, Parkinson’s disease, ALS, and others. Yet, their role in Alzheimer’s disease and related dementias (ADRDs), despite
-
Intracerebral haemorrhage — mechanisms, diagnosis and prospects for treatment and prevention Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-15 David J. Seiffge, Simon Fandler-Höfler, Yang Du, Martina B. Goeldlin, Wilmar M. T. Jolink, Catharina J. M. Klijn, David J. Werring
-
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease Mol. Neurodegener. (IF 14.9) Pub Date : 2024-11-16 Akihiro Ishii, Joseph A. Pathoulas, Omar MoustafaFathy Omar, Yingying Ge, Annie Y. Yao, Tressa Pantalena, Neeraj Singh, John Zhou, Wanxia He, Patrick Murphy, Riqiang Yan, Xiangyou Hu
The accumulation of β-amyloid (Aβ) peptides into insoluble plaques is an early pathological feature of Alzheimer’s disease (AD). BACE1 is the sole β-secretase for Aβ generation, making it an attractive therapeutic target for AD therapy. While BACE1 inhibitors have been shown to reduce Aβ levels in people with AD, clinical trials targeting BACE1 have failed due to unwanted synaptic deficits. Understanding
-
Alzheimer's Association workgroup suggests language for clinicians to talk to their patients about new treatments Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-16
The availability of US Food and Drug Administration (FDA)-approved therapies for early Alzheimer's disease (AD) challenges clinicians and health-care providers with effectively communicating the risks, benefits, burdens, costs and available support associated with these treatments to patients, families, and other health-care providers. The task is essential but complex. The Alzheimer's Association
-
Issue Information Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-16
Click on the article title to read more.
-
Spastic Paresis: A Treatable Movement Disorder. Mov. Disord. (IF 7.4) Pub Date : 2024-11-16 Jean-Michel Gracies,Katharine E Alter,Bo Biering-Sørensen,Julius P A Dewald,Dirk Dressler,Alberto Esquenazi,Jorge Hernandez Franco,Robert Jech,Ryuji Kaji,Lingjing Jin,Erle C H Lim,Preeti Raghavan,Raymond Rosales,Ali S Shalash,David M Simpson,Areerat Suputtitada,Michele Vecchio,Jörg Wissel,
-
-
-
Reply to: “Clinical and Molecular Profiling in GNAO1 Permits Phenotype–Genotype Correlation” Mov. Disord. (IF 7.4) Pub Date : 2024-11-16 Mortimer Svec, Tobias Mantel, Michael Zech, Bernhard Haslinger
-
Response to Mortimer et al. “Clinical and molecular profiling in GNAO1 permits phenotype–genotype correlation” Mov. Disord. (IF 7.4) Pub Date : 2024-11-16 Amaia Lasa‐Aranzasti, Gonzalo P. Solis, Vladimir L. Katanaev, Belén Pérez‐Dueñas
-
-
No sex difference in the extent of acute mechanical blood–brain barrier disruption after experimental concussion Acta Neuropathol. (IF 9.3) Pub Date : 2024-11-14 Hailong Song, Eashwar Kantemneni, Yue Qiu, Jean-Pierre Dolle, D. Kacy Cullen, William Stewart, Douglas H. Smith
-
Microglia contribute to the production of the amyloidogenic ABri peptide in familial British dementia Acta Neuropathol. (IF 9.3) Pub Date : 2024-11-15 Charles Arber, Jackie M. Casey, Samuel Crawford, Naiomi Rambarack, Umran Yaman, Sarah Wiethoff, Emma Augustin, Thomas M. Piers, Matthew Price, Agueda Rostagno, Jorge Ghiso, Patrick A. Lewis, Tamas Revesz, John Hardy, Jennifer M. Pocock, Henry Houlden, Jonathan M. Schott, Dervis A. Salih, Tammaryn Lashley, Selina Wray
Mutations in ITM2B cause familial British, Danish, Chinese, and Korean dementias. In familial British dementia (FBD), a mutation in the stop codon of the ITM2B gene (also known as BRI2) causes a C-terminal cleavage fragment of the ITM2B/BRI2 protein to be extended by 11 amino acids. This fragment, termed amyloid-Bri (ABri), is highly insoluble and forms extracellular plaques in the brain. ABri plaques
-
Pure LATE-NC: Frequency, clinical impact, and the importance of considering APOE genotype when assessing this and other subtypes of non-Alzheimer’s pathologies Acta Neuropathol. (IF 9.3) Pub Date : 2024-11-15 Yuriko Katsumata, Xian Wu, Khine Zin Aung, David W. Fardo, Davis C. Woodworth, S. Ahmad Sajjadi, Sandra O. Tomé, Dietmar Rudolf Thal, Juan C. Troncoso, Koping Chang, Charles Mock, Peter T. Nelson
Pure limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (pure LATE-NC) is a term used to describe brains with LATE-NC but lacking intermediate or severe levels of Alzheimer’s disease neuropathologic changes (ADNC). Focusing on pure LATE-NC, we analyzed data from the National Alzheimer’s Coordinating Center (NACC) Neuropathology Data Set, comprising clinical and pathological
-
Single-nucleus transcriptomics reveals disease- and pathology-specific signatures in α-synucleinopathies Brain (IF 10.6) Pub Date : 2024-11-15 Gonzalo S Nido, Martina Castelli, Sepideh Mostafavi, Anna Rubiolo, Omnia Shadad, Guido Alves, Ole-Bjørn Tysnes, Christian Dölle, Charalampos Tzoulis
α-synucleinopathies are progressive neurodegenerative disorders characterized by intracellular aggregation of α-synuclein, yet their molecular pathogenesis remains unknow. Here, we explore cell-specific changes in gene expression across different α-synucleinopathies. We perform single-nucleus RNA sequencing on nearly 300,000 nuclei from the prefrontal cortex of individuals with idiopathic Parkinson’s
-
Cerebral Oxygen Metabolic Stress in Children and Adults With Large Vessel Vasculopathy Due to Sickle Cell Disease. Neurology (IF 7.7) Pub Date : 2024-11-15 Yan Wang,Slim Fellah,Martin Reis,Kristin P Guilliams,Melanie E Fields,Karen Steger-May,Amy E Mirro,Josiah B Lewis,Chunwei Ying,Rachel A Cohen,Monica L Hulbert,Allison A King,Yasheng Chen,Jin-Moo Lee,Hongyu An,Andria L Ford
BACKGROUND AND OBJECTIVES Large vessel vasculopathy (LVV), or moyamoya syndrome, increases the risk of stroke in patients with sickle cell disease (SCD), yet effective treatments are lacking. In atherosclerotic carotid disease, previous studies demonstrated elevated oxygen extraction fraction (OEF) as a predictor of ipsilateral stroke. In a SCD cohort, we examined hemispheric hemodynamic and oxygen
-
Evaluating Social Determinants of Health-Based Alternatives to Race-Based Cognitive Normative Models. Neurology (IF 7.7) Pub Date : 2024-11-15 Andrea Lauren Christman Schneider,Anny Reyes,James A Henegan,Vidyulata Kamath,Lisa Wruck,James Russell Pike,Alden Gross,Keenan Walker,Anna Kucharska-Newton,Josef Coresh,Thomas H Mosley,Rebecca F Gottesman,Michael Griswold
BACKGROUND AND OBJECTIVES Race and ethnicity are proxy measures of sociocultural factors that influence cognitive test performance. Our objective was to compare different regression-based cognitive normative models adjusting for demographics and different combinations of easily accessible/commonly used social determinants of health (SDoH) factors, which may help describe cognitive performance variability
-
Child Neurology: Five-Year Update on Siblings With Riboflavin Transporter Deficiency: Stable Visual and Neurologic Status With Continued Riboflavin Therapy. Neurology (IF 7.7) Pub Date : 2024-11-15 Marisa A O'Brien,Susan M Culican,Marwan S Shinawi,Craig M Zaidman
Riboflavin transporter deficiency (RTD), previously referred to as Brown-Vialetto-Van Laere syndrome, is caused by pathogenic variants in the SLC52A1, SLC52A2, or SLC52A3 genes, resulting in RTD types 1, 2, and 3, respectively. Researchers estimate an occurrence of approximately 1 in 1,000,000. There is only one case of type 1 described in medical literature. Type 2 is characterized by muscle weakness
-
The microglial translocator protein (TSPO) in Alzheimer’s disease reflects a phagocytic phenotype Acta Neuropathol. (IF 9.3) Pub Date : 2024-11-14 Emma F. Garland, Henrike Antony, Laura Kulagowska, Thomas Scott, Charlotte Rogien, Michel Bottlaender, James A. R. Nicoll, Delphine Boche
Translocator protein (TSPO) is a mitochondrial protein expressed by microglia, ligands for which are used as a marker of neuroinflammation in PET studies of Alzheimer’s disease (AD). We previously showed increasing TSPO load in the cerebral cortex with AD progression, consistent with TSPO PET scan findings. Here, we aim to characterise the microglial phenotype associated with TSPO expression to aid
-
Public and participant involvement as a pathway to inclusive dementia research Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-14 Sarah Walter, RÍona McArdle, Emily A. Largent, Rebecca Edelmayer, Claire Sexton, Sandra Loyola Sandoval, Helen Medsger, Nancy Meserve, Roland Samaroo, Cynthia Sierra, Marlon M. P. Smeitink, Allison Gibson, Sarah Gregory, Diana Karamacoska, Iracema Leroi, Doris Molina‐Henry, Aida Suarez‐Gonzalez, Crystal M. Glover
The field of Alzheimer's disease and related dementias (ADRD) urgently requires inclusive research to ensure the priorities and outcomes of research apply to those most impacted. We postulate public and participant involvement (PPI) as a pathway to achieving the best science, both in research that informs health and social policy as well as in therapeutic studies to treat and prevent ADRD. This position
-
Additive effects of cerebrovascular disease functional connectome phenotype and plasma p‐tau181 on longitudinal neurodegeneration and cognitive outcomes Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-14 Joanna Su Xian Chong, Fang Ji, Saima Hilal, Joyce Ruifen Chong, Jia Ming Lau, Nathanael Ren Jie Tong, Boon Yeow Tan, Narayanaswamy Venketasubramanian, Mitchell Kim Peng Lai, Christopher Li‐Hsian Chen, Juan Helen Zhou
INTRODUCTIONWe investigated the effects of multiple cerebrovascular disease (CeVD) neuroimaging markers on brain functional connectivity (FC), and how such CeVD‐related FC changes interact with plasma phosphorylated tau (p‐tau)181 (an Alzheimer's disease [AD] marker) to influence downstream neurodegeneration and cognitive changes.METHODSMultivariate associations among four CeVD markers and whole‐brain
-
Cognition and maps of injury in small vessel disease: time to move on from the black and white era Brain (IF 10.6) Pub Date : 2024-11-14 Michael O’Sullivan
This scientific commentary refers to ‘Enhancing cognitive performance prediction by white matter hyperintensity connectivity assessment’ by Petersen et al. (https://doi.org/10.1093/brain/awae315).
-
Reduced brain oxygen response to spreading depolarization predicts worse outcome in ischaemic stroke Brain (IF 10.6) Pub Date : 2024-11-14 Nils Hecht, Daisy Haddad, Konrad Neumann, Leonie Schumm, Nora F Dengler, Lars Wessels, Patrick Dömer, Simeon Helgers, Franziska Meinert, Sebastian Major, Coline L Lemale, Jens P Dreier, Peter Vajkoczy, Johannes Woitzik
Spreading depolarization (SD) describes a propagating neuronal mass depolarization within the cerebral cortex that represents a mediator of infarct development and strongly stimulates the metabolic rate of O2 consumption. Here, we investigated the influence of Spreading Depolarization (SD) on brain tissue partial pressure of O2 (ptiO2) within the peri-infarct tissue of patients suffering malignant
-
Endothelial Cell Senescence Effect on the Blood-Brain Barrier in Stroke and Cognitive Impairment. Neurology (IF 7.7) Pub Date : 2024-11-14 Maria Guadalupe C Real,Sarina R Falcione,Roobina Boghozian,Michael Clarke,Raluca Todoran,Alexis St Pierre,Yiran Zhang,Twinkle Joy,Glen C Jickling
Age is an important risk factor of stroke, cognitive decline, and dementia. Senescent endothelial cells (ECs) accumulate with advancing age through exposure to cellular stress, such as that exerted by hypertension and diabetes. These senescent ECs have altered characteristics, such as altered tight junction proteins, use of a more indiscriminate transcellular transport system, increased inflammation
-
Patterns and Clinical Implications of Hemorrhagic Transformation After Thrombolysis in Acute Ischemic Stroke: Results From the ENCHANTED Study. Neurology (IF 7.7) Pub Date : 2024-11-14 Yanan Wang,Toshiki Maeda,Shoujiang You,Chen Chen,Leibo Liu,Zien Zhou,Thompson G Robinson,Richard Iain Lindley,Candice Delcourt,Grant Mair,Joanna M Wardlaw,John Philip Chalmers,Hisatomi Arima,Yining Huang,Jong S Kim,Pablo M Lavados,Tsong-Hai Lee,Christopher Levi,Mark W Parsons,Sheila Co Martins,Jeyaraj Durai Pandian,Octavio M Pontes-Neto,Vijay K Sharma,Thang Huy Nguyen,Jiguang Wang,Simiao Wu,Ming Liu
BACKGROUND AND OBJECTIVES Hemorrhagic transformation may be a potentially devastating complication of IV thrombolysis (IVT) in acute ischemic stroke, but what degree of hemorrhage indicates the greatest negative effect is not known. We aimed to define the associations between hemorrhagic transformation patterns, classified according to clinical and imaging categories, and clinical outcomes after IVT
-
Adverse Effects of Post-Recanalization Hemorrhagic Transformation: Asymptomatic but Not Inconsequential. Neurology (IF 7.7) Pub Date : 2024-11-14 Patrick D Lyden
-
Resident & Fellow Section: Commemorating 20 Years of Innovation and Growth. Neurology (IF 7.7) Pub Date : 2024-11-14 Skyler M Kane,Ariel M Lyons-Warren,Katrina Hannah D Ignacio,Kathleen M Pieper,Katherine A Fu
-
Gaps in biomedical research in frontotemporal dementia: A call for diversity and disparities focused research Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-13 Karen Nuytemans, Sanne Franzen, Iris J. Broce, Paulo Caramelli, Ratnavalli Ellajosyula, Elizabeth Finger, Veer Gupta, Vivek Gupta, Ignacio Illán-Gala, Samantha M. Loi, Darby Morhardt, Yolande Pijnenburg, Katya Rascovsky, Monique M. Williams, Jennifer S. Yokoyama, Juliana Acosta-Uribe, Rufus Akinyemi, Suvarna Alladi, Biniyam A. Ayele, Yavuz Ayhan, Renelle Bourdage, Sheila Castro-Suarez, Leonardo Cruz
Frontotemporal dementia (FTD) is one of the leading causes of young-onset dementia before age 65, typically manifesting as abnormal behavior (in behavioral variant FTD) or language impairment (in primary progressive aphasia). Although FTD affects all populations across the globe, knowledge regarding the pathophysiology and genetics derives primarily from studies conducted in North America and Western
-
Integrated cerebellar radiomic-network model for predicting mild cognitive impairment in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-13 Yini Chen, Yiwei Qi, Yiying Hu, Xinhui Qiu, Tao Qiu, Song Li, Meichen Liu, Qiqi Jia, Bo Sun, Cong Liu, Tianbai Li, Weidong Le
Pathological and neuroimaging alterations in the cerebellum of Alzheimer's disease (AD) patients have been documented. However, the role of cerebellum-derived radiomic and structural connectome modeling in the prediction of AD progression remains unclear.